Results 91 to 100 of about 4,368 (201)

Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification

Frontiers in Pharmacology
IntroductionDiabetic nephropathy (DN) is a serious complication of diabetes with limited therapeutic options. Although Huangkui capsule (HKC) and finerenone individually show potential in DN management, their combined mechanism remains unclear.
Xuanke Liu, Chunjiang Zhang, YanJie Fu, JingJing Dai, Jiaying Lu, Gang Liu, Xiaoping Yang   +6 more
doaj   +1 more source

Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study

Metabolism Open
Aim/introduction: Early therapeutic interventions are necessary to reduce cardiovascular and renal composite endpoints in individuals with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD).
Yuji Kawaguchi, Yuriko Hajika, Narumi Ashida, Maho Rinka, Chie Hamai, Koji Masumoto, Jun Sawa, Kenji Hamazaki, Yasuro Kumeda   +8 more
doaj   +1 more source

Finerenone: Fiddling With Hyperkalemia? [PDF]

American Journal of Kidney Diseases, 2021
Joshua Waitzman, Mark Canney, Swapnil Hiremath   +2 more
openaire   +2 more sources

Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)

Cardiovascular Diabetology
Background The mechanisms underlying cardiorenal benefits of finerenone remain unclear. This mechanistic trial aimed to evaluate the effects of finerenone on vascular stiffness, as assessed using the cardio-ankle vascular index (CAVI), and cardiorenal ...
Atsushi Tanaka, Muthiah Vaduganathan, Takumi Imai, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Satoru Suwa, Hiroki Teragawa, Motoaki Miyazono, Makoto Fukuda, Keisuke Yonezu, Naohiko Takahashi, Yuichi Yoshida, Kenichi Tanaka, Michio Shimabukuro, Yuki Hotta, Masao Moroi, Hiroki Niikura, Keisuke Kida, Kenichi Yokota, Daiju Fukuda, Kengo Tanabe, Yu Horiuchi, Shigeru Toyoda, Isao Taguchi, Hisako Yoshida, Toru Miyoshi, Masaomi Nangaku, Hirotaka Shibata, Koichi Node, on behalf of the FIVE-STAR Investigators   +30 more
doaj   +1 more source

Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Kidney Diseases
Introduction: In FIDELITY, a prespecified pooled analysis of the phase III FIDELIO-DKD and FIGARO-DKD trials, finerenone reduced the risk of cardiovascular (CV) and kidney events versus placebo in patients with type 2 diabetes and chronic ...
Takashi Wada, Stefan D. Anker, Zhihong Liu, Byung Wan Lee, Chien-Te Lee, Peter Rossing, Luis M. Ruilope, Christiane Ahlers, Meike Brinker, Amaninder Mann, Satoshi Yamashita, Bertram Pitt   +11 more
doaj   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications.
Ixchel Lima Posada, Matthieu Soulié, Yohan Stephan, Roberto Palacios Ramirez, Benjamin Bonnard, Lionel Nicol, Bertram Pitt, Peter Kolkhof, Paul Mulder, Frederic Jaisser   +9 more
doaj   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD
Ashish Verma, Ashish Upadhyay
openaire   +2 more sources

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

, 2016
Background Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD.
Joseph, A., Anker, S.D., Rossing, P., Kolkhof, P., Ruilope, L.M., Wilson, D.J., Agarwal, R., Lawatscheck, R., Filippatos, G., Pitt, B., Bakris, G.L., Scott, C.   +11 more
core   +1 more source

Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated greater receptor selectivity and fewer adverse effects compared with older mineralocorticoid receptor antagonists.
Yara Jelwan, Tianyu Cao, Zhiqi Yao, Semenawit Burka, John Erhabor, Phillip Berning, Omar Dzaye, Michael Blaha   +7 more
doaj   +1 more source

Focus on finerenone: the FINEARTS-HF study

European Heart Journal Supplements
Abstract Mineralcorticoid receptor (MR) blockade is a mainstay of treatment for heart failure with reduced ejection fraction (HFrEF); however, the benefit is less well established in heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).
Tolone, Stefano, Tinti, Maria Denitza, Pulignano, Giovanni, Natale, Enrico, Gabrielli, Domenico   +4 more
openaire   +2 more sources